{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3345, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de074-6fae-7498-8419-f22001296f52", "docSlug": "0236852313362726d8a2c733e0652efc", "documentTitle": "Advantage Solutions | Results Presentation Deck | 13 slides", "authorId": "advantage-solutions", "authorName": "Advantage Solutions", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/aOWy_NJexlH0BR2b0vTjdPN-jpmuosp1p37etTcpSgQ/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wMjM2ODUyMzEzMzYyNzI2ZDhhMmM3MzNlMDY1MmVmYy9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-6fae-7498-8419-f22001296f52/1", "deckHref": "/decks/019de074-6fae-7498-8419-f22001296f52", "deckAnchorHref": "/decks/019de074-6fae-7498-8419-f22001296f52#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 1, "from": 1, "beatId": "caffe889-5f13-45ef-b0fd-1d845dd7a532", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Attention", "beatSlug": "aida-attention", "evidence": "The cover slide grabs the audience's attention.", "position": 0, "confidence": 0.8, "parentBeatName": "Hook", "parentBeatSlug": "hook" } ], "imagePathAlt": "https://imgproxy.kitesheet.com/6O69g1Z0oK1O53LEbP8sIqewsoTCHE88z6PIJh2YnI0/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wMjM2ODUyMzEzMzYyNzI2ZDhhMmM3MzNlMDY1MmVmYy9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/oSGLymIAR83iDLmJBsRraJ8mVf0TnTr1Gvyxgx4afGg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wMjM2ODUyMzEzMzYyNzI2ZDhhMmM3MzNlMDY1MmVmYy9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/ZiQSIa_cEl5yLzXTsATtf8vro6pDl8o3q0dAHa4Vh1E/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wMjM2ODUyMzEzMzYyNzI2ZDhhMmM3MzNlMDY1MmVmYy9wMDAxLnBuZw" }, { "docId": "019de074-6fae-7498-8419-f22001296f52", "docSlug": "0236852313362726d8a2c733e0652efc", "documentTitle": "Advantage Solutions | Results Presentation Deck | 13 slides", "authorId": "advantage-solutions", "authorName": "Advantage Solutions", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-6fae-7498-8419-f22001296f52/2", "deckHref": "/decks/019de074-6fae-7498-8419-f22001296f52", "deckAnchorHref": "/decks/019de074-6fae-7498-8419-f22001296f52#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-6fae-7498-8419-f22001296f52", "docSlug": "0236852313362726d8a2c733e0652efc", "documentTitle": "Advantage Solutions | Results Presentation Deck | 13 slides", "authorId": "advantage-solutions", "authorName": "Advantage Solutions", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "key_messages", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-6fae-7498-8419-f22001296f52/3", "deckHref": "/decks/019de074-6fae-7498-8419-f22001296f52", "deckAnchorHref": "/decks/019de074-6fae-7498-8419-f22001296f52#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-6fae-7498-8419-f22001296f52", "docSlug": "0236852313362726d8a2c733e0652efc", "documentTitle": "Advantage Solutions | Results Presentation Deck | 13 slides", "authorId": "advantage-solutions", "authorName": "Advantage Solutions", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide presents a 3x2 grid of bar charts comparing revenue and EBITDA for Total Advantage, Sales Segment, and Marketing Segment.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-6fae-7498-8419-f22001296f52/4", "deckHref": "/decks/019de074-6fae-7498-8419-f22001296f52", "deckAnchorHref": "/decks/019de074-6fae-7498-8419-f22001296f52#slide-4", "loopMatches": [ { "to": 5, "from": 4, "name": "So What Cascade", "slug": "41-so-what-cascade", "bestFor": "Data presentations, executive summaries, driving to recommendations", "matchId": "38b4bf87-a408-4907-b48e-4ab997d097a0", "evidence": "The financial results slides provide an overview of the company's performance, and the implications for the future are implied.", "position": 1, "objective": "What do the financial results mean for the company's future?", "structure": "The Data -> So What? (Insight 1) -> So What? (Insight 2) -> So What? (The Action)", "confidence": 0.6, "description": "Chain insights together, each answering 'so what?' until you reach the actionable conclusion" } ], "arcBeatMatches": [ { "to": 5, "from": 4, "beatId": "a0d69b83-e58b-4516-b344-43c8071583b7", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Overview", "beatSlug": null, "evidence": "The slides provide an overview of quarterly financial results and healthy revenue trends.", "position": 1, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-6fae-7498-8419-f22001296f52", "docSlug": "0236852313362726d8a2c733e0652efc", "documentTitle": "Advantage Solutions | Results Presentation Deck | 13 slides", "authorId": "advantage-solutions", "authorName": "Advantage Solutions", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "kpi_overview", "function": "analyze_data", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-6fae-7498-8419-f22001296f52/5", "deckHref": "/decks/019de074-6fae-7498-8419-f22001296f52", "deckAnchorHref": "/decks/019de074-6fae-7498-8419-f22001296f52#slide-5", "loopMatches": [ { "to": 5, "from": 4, "name": "So What Cascade", "slug": "41-so-what-cascade", "bestFor": "Data presentations, executive summaries, driving to recommendations", "matchId": "38b4bf87-a408-4907-b48e-4ab997d097a0", "evidence": "The financial results slides provide an overview of the company's performance, and the implications for the future are implied.", "position": 1, "objective": "What do the financial results mean for the company's future?", "structure": "The Data -> So What? (Insight 1) -> So What? (Insight 2) -> So What? (The Action)", "confidence": 0.6, "description": "Chain insights together, each answering 'so what?' until you reach the actionable conclusion" } ], "arcBeatMatches": [ { "to": 5, "from": 4, "beatId": "a0d69b83-e58b-4516-b344-43c8071583b7", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Overview", "beatSlug": null, "evidence": "The slides provide an overview of quarterly financial results and healthy revenue trends.", "position": 1, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-6fae-7498-8419-f22001296f52", "docSlug": "0236852313362726d8a2c733e0652efc", "documentTitle": "Advantage Solutions | Results Presentation Deck | 13 slides", "authorId": "advantage-solutions", "authorName": "Advantage Solutions", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-6fae-7498-8419-f22001296f52/6", "deckHref": "/decks/019de074-6fae-7498-8419-f22001296f52", "deckAnchorHref": "/decks/019de074-6fae-7498-8419-f22001296f52#slide-6", "loopMatches": [ { "to": 6, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "c23cc10b-29ae-4e70-b1aa-e5de4d38f2ef", "evidence": "The 2023 outlook slide implies that not acting on the presented plan may have negative consequences.", "position": 0, "objective": "What are the consequences of not acting on the 2023 outlook?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 6, "from": 6, "beatId": "dd248d68-330f-4f8e-b060-886a54d6607f", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Key Takeaways", "beatSlug": null, "evidence": "The slide presents key takeaways, including the 2023 outlook.", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-6fae-7498-8419-f22001296f52", "docSlug": "0236852313362726d8a2c733e0652efc", "documentTitle": "Advantage Solutions | Results Presentation Deck | 13 slides", "authorId": "advantage-solutions", "authorName": "Advantage Solutions", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "kpi_overview", "function": "analyze_data", "notes": "Includes a waterfall-style chart showing debt components and a detailed table for debt and equity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-6fae-7498-8419-f22001296f52/7", "deckHref": "/decks/019de074-6fae-7498-8419-f22001296f52", "deckAnchorHref": "/decks/019de074-6fae-7498-8419-f22001296f52#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 7, "from": 7, "beatId": "c3f31970-0b01-4016-9cc4-bb02f62e3285", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Capitalization Summary", "beatSlug": null, "evidence": "The slide provides a capitalization summary.", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-6fae-7498-8419-f22001296f52", "docSlug": "0236852313362726d8a2c733e0652efc", "documentTitle": "Advantage Solutions | Results Presentation Deck | 13 slides", "authorId": "advantage-solutions", "authorName": "Advantage Solutions", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "appendix_data", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-6fae-7498-8419-f22001296f52/8", "deckHref": "/decks/019de074-6fae-7498-8419-f22001296f52", "deckAnchorHref": "/decks/019de074-6fae-7498-8419-f22001296f52#slide-8", "loopMatches": [], "arcBeatMatches": [ { "to": 12, "from": 8, "beatId": "62f68eb5-7566-49c2-b0fb-cea994cc5af5", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Appendix", "beatSlug": null, "evidence": "The slides provide additional data and reconciliation information.", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-6fae-7498-8419-f22001296f52", "docSlug": "0236852313362726d8a2c733e0652efc", "documentTitle": "Advantage Solutions | Results Presentation Deck | 13 slides", "authorId": "advantage-solutions", "authorName": "Advantage Solutions", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes footnotes references (1) through (9) which are not explicitly rendered on this slide.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-6fae-7498-8419-f22001296f52/9", "deckHref": "/decks/019de074-6fae-7498-8419-f22001296f52", "deckAnchorHref": "/decks/019de074-6fae-7498-8419-f22001296f52#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 12, "from": 8, "beatId": "62f68eb5-7566-49c2-b0fb-cea994cc5af5", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Appendix", "beatSlug": null, "evidence": "The slides provide additional data and reconciliation information.", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-6fae-7498-8419-f22001296f52", "docSlug": "0236852313362726d8a2c733e0652efc", "documentTitle": "Advantage Solutions | Results Presentation Deck | 13 slides", "authorId": "advantage-solutions", "authorName": "Advantage Solutions", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide presents two separate tables for Sales and Marketing segments, detailing various add-backs and adjustments to arrive at Adjusted EBITDA.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-6fae-7498-8419-f22001296f52/10", "deckHref": "/decks/019de074-6fae-7498-8419-f22001296f52", "deckAnchorHref": "/decks/019de074-6fae-7498-8419-f22001296f52#slide-10", "loopMatches": [], "arcBeatMatches": [ { "to": 12, "from": 8, "beatId": "62f68eb5-7566-49c2-b0fb-cea994cc5af5", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Appendix", "beatSlug": null, "evidence": "The slides provide additional data and reconciliation information.", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-6fae-7498-8419-f22001296f52", "docSlug": "0236852313362726d8a2c733e0652efc", "documentTitle": "Advantage Solutions | Results Presentation Deck | 13 slides", "authorId": "advantage-solutions", "authorName": "Advantage Solutions", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "appendix_data", "function": "analyze_data", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-6fae-7498-8419-f22001296f52/11", "deckHref": "/decks/019de074-6fae-7498-8419-f22001296f52", "deckAnchorHref": "/decks/019de074-6fae-7498-8419-f22001296f52#slide-11", "loopMatches": [], "arcBeatMatches": [ { "to": 12, "from": 8, "beatId": "62f68eb5-7566-49c2-b0fb-cea994cc5af5", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Appendix", "beatSlug": null, "evidence": "The slides provide additional data and reconciliation information.", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-6fae-7498-8419-f22001296f52", "docSlug": "0236852313362726d8a2c733e0652efc", "documentTitle": "Advantage Solutions | Results Presentation Deck | 13 slides", "authorId": "advantage-solutions", "authorName": "Advantage Solutions", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "appendix_disclosure", "function": "appendix", "notes": "This is the fourth page of a four-part appendix disclosure regarding non-GAAP financial measures.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-6fae-7498-8419-f22001296f52/12", "deckHref": "/decks/019de074-6fae-7498-8419-f22001296f52", "deckAnchorHref": "/decks/019de074-6fae-7498-8419-f22001296f52#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 12, "from": 8, "beatId": "62f68eb5-7566-49c2-b0fb-cea994cc5af5", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Appendix", "beatSlug": null, "evidence": "The slides provide additional data and reconciliation information.", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-6fae-7498-8419-f22001296f52", "docSlug": "0236852313362726d8a2c733e0652efc", "documentTitle": "Advantage Solutions | Results Presentation Deck | 13 slides", "authorId": "advantage-solutions", "authorName": "Advantage Solutions", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "closing_ask", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-6fae-7498-8419-f22001296f52/13", "deckHref": "/decks/019de074-6fae-7498-8419-f22001296f52", "deckAnchorHref": "/decks/019de074-6fae-7498-8419-f22001296f52#slide-13", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": "Includes company logo, tagline, date, and ticker symbol.", "imagePath": "https://imgproxy.kitesheet.com/dcgcdbpEp8yeRm0ty-yp7wqu9i1bV8lE19VQS0d1LxE/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85YjgxZDhhMDljNjlhZmMzZjEzOWRjOTcwZWZmYWJkZS9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/1", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/3U1RSgJSbfcQ0ll6fKWa75ZDHCC7sSyxmkQiZ-Oc7lM/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85YjgxZDhhMDljNjlhZmMzZjEzOWRjOTcwZWZmYWJkZS9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/sRjBZkeEk9lAnlKkXDzPJtokwRoErv22faRSnhhfYG8/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85YjgxZDhhMDljNjlhZmMzZjEzOWRjOTcwZWZmYWJkZS9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/UsihJHe17YxIgXwjdT9youhMPJr0kwJLtFhEyTAJ6k0/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85YjgxZDhhMDljNjlhZmMzZjEzOWRjOTcwZWZmYWJkZS9wMDAxLnBuZw" }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/2", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "mission", "function": "inspire_vision", "notes": "The slide uses a split-screen layout with a photo on the left and text on a dark blue background on the right.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/3", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-3", "loopMatches": [ { "to": 5, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "3c4d5c18-10a6-4d45-b290-19c7a6f7c4ba", "evidence": "The document presents Aeglea BioTherapeutics' mission and vision for redefining the possible with human enzyme therapies.", "position": 1, "objective": "Why does Aeglea BioTherapeutics exist?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "mission", "function": "inspire_vision", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/4", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-4", "loopMatches": [ { "to": 5, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "3c4d5c18-10a6-4d45-b290-19c7a6f7c4ba", "evidence": "The document presents Aeglea BioTherapeutics' mission and vision for redefining the possible with human enzyme therapies.", "position": 1, "objective": "Why does Aeglea BioTherapeutics exist?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a Gantt-style chart to represent clinical trial progress for three distinct programs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/5", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-5", "loopMatches": [ { "to": 5, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "3c4d5c18-10a6-4d45-b290-19c7a6f7c4ba", "evidence": "The document presents Aeglea BioTherapeutics' mission and vision for redefining the possible with human enzyme therapies.", "position": 1, "objective": "Why does Aeglea BioTherapeutics exist?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "traction", "function": "show_traction", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/6", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-6", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/7", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-7", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "problem_statement", "function": "frame_problem", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/8", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-8", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 8, "beatId": "6cb53ed7-58ff-4ea0-ac83-e1c303e5033e", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "The document identifies the problems associated with classical homocystinuria and arginase 1 deficiency.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "pain_points", "function": "frame_problem", "notes": "Includes two testimonials from Key Opinion Leaders (KOLs) to emphasize the difficulty of treatment compliance.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/9", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 8, "beatId": "6cb53ed7-58ff-4ea0-ac83-e1c303e5033e", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "The document identifies the problems associated with classical homocystinuria and arginase 1 deficiency.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 10, "from": 9, "beatId": "1d9afea3-dabd-41fb-b0e2-430e750a2acb", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document agitates the need for better treatment options by highlighting the serious and potentially deadly complications associated with these disorders.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a pie chart for segmentation and a timeline/number line for diagnostic age, followed by key clinical metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/10", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-10", "loopMatches": [ { "to": 11, "from": 10, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "7b5956cf-b800-4aec-9392-9fb9fb1da892", "evidence": "The document presents a market sizing analysis for classical homocystinuria.", "position": 2, "objective": "What is the market opportunity for Aeglea BioTherapeutics' therapies?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.6, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 10, "from": 9, "beatId": "1d9afea3-dabd-41fb-b0e2-430e750a2acb", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document agitates the need for better treatment options by highlighting the serious and potentially deadly complications associated with these disorders.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "solution", "function": "present_solution", "notes": "Includes a biological process diagram showing intracellular vs plasma metabolism.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/11", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-11", "loopMatches": [ { "to": 11, "from": 10, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "7b5956cf-b800-4aec-9392-9fb9fb1da892", "evidence": "The document presents a market sizing analysis for classical homocystinuria.", "position": 2, "objective": "What is the market opportunity for Aeglea BioTherapeutics' therapies?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.6, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 15, "from": 11, "beatId": "e2814c7d-564b-4c74-ad47-085d9e1b3afc", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Aeglea BioTherapeutics' therapies as a solution to the problems associated with classical homocystinuria and arginase 1 deficiency.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "traction", "function": "show_traction", "notes": "The chart shows a clear dose-response relationship between 1.0 mg/kg and 10.0 mg/kg doses, with statistical significance marked at early time points.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/12", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 15, "from": 11, "beatId": "e2814c7d-564b-4c74-ad47-085d9e1b3afc", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Aeglea BioTherapeutics' therapies as a solution to the problems associated with classical homocystinuria and arginase 1 deficiency.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "traction", "function": "show_traction", "notes": "The slide uses two distinct chart types (Kaplan-Meier survival curve and a time-series pharmacodynamic plot) to demonstrate drug efficacy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/13", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 15, "from": 11, "beatId": "e2814c7d-564b-4c74-ad47-085d9e1b3afc", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Aeglea BioTherapeutics' therapies as a solution to the problems associated with classical homocystinuria and arginase 1 deficiency.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide outlines a two-part clinical trial structure with specific cohorts and patient criteria.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/14", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 15, "from": 11, "beatId": "e2814c7d-564b-4c74-ad47-085d9e1b3afc", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Aeglea BioTherapeutics' therapies as a solution to the problems associated with classical homocystinuria and arginase 1 deficiency.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/15", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 15, "from": 11, "beatId": "e2814c7d-564b-4c74-ad47-085d9e1b3afc", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Aeglea BioTherapeutics' therapies as a solution to the problems associated with classical homocystinuria and arginase 1 deficiency.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/16", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-16", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "problem_statement", "function": "frame_problem", "notes": "Includes a timeline-based progression of symptoms from infancy to adulthood.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/17", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-17", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "context", "function": "establish_context", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/18", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-18", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "traction", "function": "show_traction", "notes": "Includes statistical significance markers and clinical guideline thresholds.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/19", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-19", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "traction", "function": "show_traction", "notes": "Includes statistical significance (p-values) and MCID reference lines for GMFM-E.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/20", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-20", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a heatmap to visualize individual patient outcomes, a common technique in clinical trial reporting.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/21", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-21", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "appendix_data", "function": "analyze_data", "notes": "Data presented as n (%).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/22", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-22", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "roadmap", "function": "plan_implementation", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/23", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-23", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/24", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-24", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "traction", "function": "show_traction", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/25", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-25", "loopMatches": [], "arcBeatMatches": [ { "to": 26, "from": 25, "beatId": "ee42496b-f81a-4970-8acd-44ab2cd043a3", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact and Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document highlights the impact of Aeglea BioTherapeutics' therapies and outlines next steps for the company.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes footnotes detailing cash equivalents and share breakdown.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/26", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-26", "loopMatches": [], "arcBeatMatches": [ { "to": 26, "from": 25, "beatId": "ee42496b-f81a-4970-8acd-44ab2cd043a3", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact and Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document highlights the impact of Aeglea BioTherapeutics' therapies and outlines next steps for the company.", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/27", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a process flow diagram to contrast intracellular metabolism with plasma-based enzymatic intervention.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/28", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "problem_statement", "function": "frame_problem", "notes": "The slide uses a Kaplan-Meier survival curve and a comparative table to illustrate the severity of the disease.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/29", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-29", "loopMatches": [ { "to": 30, "from": 29, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e9fd3069-3f5b-45da-9881-bc31a8be9bc6", "evidence": "The document highlights the increased mortality and high risk of severe complications associated with classical homocystinuria.", "position": 0, "objective": "What are the consequences of not treating classical homocystinuria?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "traction", "function": "show_traction", "notes": "Includes histological images of liver tissue and a dot plot showing BMD improvement.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/30", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-30", "loopMatches": [ { "to": 30, "from": 29, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e9fd3069-3f5b-45da-9881-bc31a8be9bc6", "evidence": "The document highlights the increased mortality and high risk of severe complications associated with classical homocystinuria.", "position": 0, "objective": "What are the consequences of not treating classical homocystinuria?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "appendix_data", "function": "analyze_data", "notes": "Clinical trial baseline data table.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/31", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "appendix_data", "function": "analyze_data", "notes": "The table displays mean/SD and median/range for continuous variables, and counts/percentages for categorical variables.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/32", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a box plot to visualize longitudinal clinical trial data.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/33", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "traction", "function": "show_traction", "notes": "Includes both continuous mean change data and categorical responder analysis.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/34", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "traction", "function": "analyze_data", "notes": "Includes a study design timeline and clinical endpoint data tables/charts.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/35", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-35", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "context", "function": "establish_context", "notes": "The slide uses standard clinical metrics for motor function assessment.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/36", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-36", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The slide uses a process flow diagram to illustrate the clinical trial structure.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/37", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-37", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "traction", "function": "show_traction", "notes": "The table highlights specific clinical improvements for six individual patients, emphasizing normalization of mobility.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/38", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-38", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-704c-735b-b7a3-613838aa1bf3", "docSlug": "9b81d8a09c69afc3f139dc970effabde", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "go_to_market", "function": "plan_implementation", "notes": "The slide uses a split-screen layout: left side is market sizing/segmentation, right side is a 2x2 strategic framework for launch execution.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/39", "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3", "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-39", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-711f-7790-9984-d11a892de9a9", "docSlug": "6d5e23bb50d3f4d85c1fd40583ae2cb4", "documentTitle": "Aeva | Results Presentation Deck | 14 slides", "authorId": "aeva", "authorName": "Aeva", "documentKindSlug": "shareholder-letter", "documentKindLabel": "Shareholder letter", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/2Fv-gSA9WmqigkPkBGYifyQzh1akDi14b-XX7HDiQEc/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82ZDVlMjNiYjUwZDNmNGQ4NWMxZmQ0MDU4M2FlMmNiNC9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-711f-7790-9984-d11a892de9a9/1", "deckHref": "/decks/019de074-711f-7790-9984-d11a892de9a9", "deckAnchorHref": "/decks/019de074-711f-7790-9984-d11a892de9a9#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 1, "from": 1, "beatId": "b438a58c-fa40-48c8-aa76-3a72700de221", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Attention", "beatSlug": "aida-attention", "evidence": "The cover page grabs attention with 2022 results", "position": 0, "confidence": 0.8, "parentBeatName": "Hook", "parentBeatSlug": "hook" } ], "imagePathAlt": "https://imgproxy.kitesheet.com/qwV6borCXwnaKhtX4J8s3FIWfpmRNsx3vPdrOp7hYCs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82ZDVlMjNiYjUwZDNmNGQ4NWMxZmQ0MDU4M2FlMmNiNC9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/rkXh3C1LB_DodWg62NFHT6-3EuSuRtcnGX-4WG5INrk/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82ZDVlMjNiYjUwZDNmNGQ4NWMxZmQ0MDU4M2FlMmNiNC9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/E-K4cRo7QfbTkv-72BNUpnTkNwWSloKQcmTSH4IWqkY/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82ZDVlMjNiYjUwZDNmNGQ4NWMxZmQ0MDU4M2FlMmNiNC9wMDAxLnBuZw" }, { "docId": "019de074-711f-7790-9984-d11a892de9a9", "docSlug": "6d5e23bb50d3f4d85c1fd40583ae2cb4", "documentTitle": "Aeva | Results Presentation Deck | 14 slides", "authorId": "aeva", "authorName": "Aeva", "documentKindSlug": "shareholder-letter", "documentKindLabel": "Shareholder letter", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-711f-7790-9984-d11a892de9a9/2", "deckHref": "/decks/019de074-711f-7790-9984-d11a892de9a9", "deckAnchorHref": "/decks/019de074-711f-7790-9984-d11a892de9a9#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-711f-7790-9984-d11a892de9a9", "docSlug": "6d5e23bb50d3f4d85c1fd40583ae2cb4", "documentTitle": "Aeva | Results Presentation Deck | 14 slides", "authorId": "aeva", "authorName": "Aeva", "documentKindSlug": "shareholder-letter", "documentKindLabel": "Shareholder letter", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "disclaimer", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-711f-7790-9984-d11a892de9a9/3", "deckHref": "/decks/019de074-711f-7790-9984-d11a892de9a9", "deckAnchorHref": "/decks/019de074-711f-7790-9984-d11a892de9a9#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-711f-7790-9984-d11a892de9a9", "docSlug": "6d5e23bb50d3f4d85c1fd40583ae2cb4", "documentTitle": "Aeva | Results Presentation Deck | 14 slides", "authorId": "aeva", "authorName": "Aeva", "documentKindSlug": "shareholder-letter", "documentKindLabel": "Shareholder letter", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "agenda", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-711f-7790-9984-d11a892de9a9/4", "deckHref": "/decks/019de074-711f-7790-9984-d11a892de9a9", "deckAnchorHref": "/decks/019de074-711f-7790-9984-d11a892de9a9#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-711f-7790-9984-d11a892de9a9", "docSlug": "6d5e23bb50d3f4d85c1fd40583ae2cb4", "documentTitle": "Aeva | Results Presentation Deck | 14 slides", "authorId": "aeva", "authorName": "Aeva", "documentKindSlug": "shareholder-letter", "documentKindLabel": "Shareholder letter", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-711f-7790-9984-d11a892de9a9/5", "deckHref": "/decks/019de074-711f-7790-9984-d11a892de9a9", "deckAnchorHref": "/decks/019de074-711f-7790-9984-d11a892de9a9#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 5, "beatId": "4e16a75a-1042-4ccb-abec-f212831503d2", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Interest", "beatSlug": "aida-interest", "evidence": "The executive summary generates interest with 2022 highlights", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-711f-7790-9984-d11a892de9a9", "docSlug": "6d5e23bb50d3f4d85c1fd40583ae2cb4", "documentTitle": "Aeva | Results Presentation Deck | 14 slides", "authorId": "aeva", "authorName": "Aeva", "documentKindSlug": "shareholder-letter", "documentKindLabel": "Shareholder letter", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-711f-7790-9984-d11a892de9a9/6", "deckHref": "/decks/019de074-711f-7790-9984-d11a892de9a9", "deckAnchorHref": "/decks/019de074-711f-7790-9984-d11a892de9a9#slide-6", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-711f-7790-9984-d11a892de9a9", "docSlug": "6d5e23bb50d3f4d85c1fd40583ae2cb4", "documentTitle": "Aeva | Results Presentation Deck | 14 slides", "authorId": "aeva", "authorName": "Aeva", "documentKindSlug": "shareholder-letter", "documentKindLabel": "Shareholder letter", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "customer_journey", "function": "illustrate_case", "notes": "The slide uses a linear process flow to demonstrate the progression of a customer engagement.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-711f-7790-9984-d11a892de9a9/7", "deckHref": "/decks/019de074-711f-7790-9984-d11a892de9a9", "deckAnchorHref": "/decks/019de074-711f-7790-9984-d11a892de9a9#slide-7", "loopMatches": [ { "to": 9, "from": 7, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "63059dae-11f0-41bc-9a35-1957798af9e8", "evidence": "The customer journey and competitive analysis slides provide an aha moment", "position": 0, "objective": "What makes Aeva's technology unique?", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.6, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-711f-7790-9984-d11a892de9a9", "docSlug": "6d5e23bb50d3f4d85c1fd40583ae2cb4", "documentTitle": "Aeva | Results Presentation Deck | 14 slides", "authorId": "aeva", "authorName": "Aeva", "documentKindSlug": "shareholder-letter", "documentKindLabel": "Shareholder letter", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "Uses a 2x2-style quadrant map to illustrate competitive advantage.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-711f-7790-9984-d11a892de9a9/8", "deckHref": "/decks/019de074-711f-7790-9984-d11a892de9a9", "deckAnchorHref": "/decks/019de074-711f-7790-9984-d11a892de9a9#slide-8", "loopMatches": [ { "to": 9, "from": 7, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "63059dae-11f0-41bc-9a35-1957798af9e8", "evidence": "The customer journey and competitive analysis slides provide an aha moment", "position": 0, "objective": "What makes Aeva's technology unique?", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.6, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }